BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, March 18, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Sep. 15, 2010
View Archived Issues
Roche, reMYND in Pact to Develop PD, AD Drugs
Roche AG and reMYND will join forces to develop two classes of compounds against Parkinson's disease and Alzheimer's disease. The total deal is worth as much as $637 million to reMYND as milestones are met. (BioWorld International)
Read More
Acceleron, Shire Partner in $498M Orphan Disease Deal
Read More
Transgene Stock Rises on Jennerex Oncolytic Virus Deal
Read More
Ark Rebuilds Post-Cerepro Failure, Headcount Cut
Read More
Abiraterone Improves Survival in Prostate Cancer Phase III
Read More
Pharming Closes $20M Deal for Rhucin with Santarus
Read More
Other News To Note
Read More